Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoSil Medical Ltd ( (AU:OSL) ) has issued an announcement.
OncoSil Medical Ltd reported a strong quarter with record dose sales in Q4 FY25, driven by increased clinical adoption and demand from treatment centers. The company achieved a 20% increase in dose sales compared to the previous quarter and a 42% increase for the full fiscal year, leading to a 66% rise in annual revenue. Additionally, OncoSil Medical completed a successful $8.7 million capital raise to support commercialization efforts and signed a distribution agreement for Slovenia. The company also announced a significant clinical study in Germany, which could enhance its market positioning by generating evidence for national reimbursement. Furthermore, a comparative study presented at Digestive Disease Week 2025 demonstrated superior outcomes for patients treated with OncoSil™ compared to Stereotactic Body Radiation Therapy, highlighting its potential as a valuable treatment option.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a medical device company specializing in localized treatments for patients with unresectable locally advanced pancreatic cancer. The company focuses on developing and commercializing its OncoSil™ device, which is designed to improve treatment outcomes for pancreatic cancer patients.
Average Trading Volume: 45,246
Technical Sentiment Signal: Sell
Current Market Cap: A$21.46M
For detailed information about OSL stock, go to TipRanks’ Stock Analysis page.